IFNG and neoplasm: In a randomized clinical trial with inoperable metastatic CRC patients, low-dose CY treatment resulted in delayed tumor progression associated with an increase in IFNγ+ anti-tumor T-cell responses, and reduction of Treg cells, B cells, and NK cells (274, 275).